Bicara Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 9.13 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 604.16M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.